Kite Pharma, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 132 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-06-20: Reporting owner Kazam Joshua A; Form 4; Security Director Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-06-20: Reporting owner Nussbaum Ran; Form 4; Security Director Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-06-20: Reporting owner Ruchefsky Steven B; Form 4; Security Director Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-06-20: Reporting owner Peacock Jonathan M; Form 4; Security Director Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-06-20 | Kazam Joshua A Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 | |
| 2017-06-20 | Nussbaum Ran Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 | |
| 2017-06-20 | Ruchefsky Steven B Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 | |
| 2017-06-20 | Peacock Jonathan M Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 | |
| 2017-06-20 | WITTE OWEN N. Director | 4 | Director Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +8,810 8,810 owned after | $91.21 exercise price | 2017-06-22 | |
| 2017-06-09 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 115,394 owned after | $1.35 exercise price | 2017-06-12 | |
| 2017-06-01 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,400 50,099 owned after | $51.43 exercise price | 2017-06-05 | |
| 2017-05-01 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,400 156,501 owned after | $53.90 exercise price | 2017-05-03 | |
| 2017-05-01 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 123,000 owned after | $6.89 exercise price | 2017-05-03 | |
| 2017-04-25 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 125,394 owned after | $1.35 exercise price | 2017-04-27 | |
| 2017-04-03 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 143,000 owned after | $6.89 exercise price | 2017-04-04 | |
| 2017-04-03 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,400 158,901 owned after | $53.90 exercise price | 2017-04-04 | |
| 2017-04-03 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 140,394 owned after | $1.35 exercise price | 2017-04-04 | |
| 2017-03-27 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 145,394 owned after | $1.35 exercise price | 2017-03-28 | |
| 2017-03-16 holding as of filing | WITTE OWEN N. Director | 3 | Option to Purchase Common Stock (Right to Buy) Derivative · Direct | Holding | $62.44 exercise price | 2017-03-16 | ||
| 2017-03-16 holding as of filing | WITTE OWEN N. Director | 3 | Option to Purchase Common Stock (Right to Buy) Derivative · Direct | Holding | $55.09 exercise price | 2017-03-16 | ||
| 2017-03-16 holding as of filing | WITTE OWEN N. Director | 3 | Option to Purchase Common Stock (Right to Buy) Derivative · Direct | Holding | $6.89 exercise price | 2017-03-16 | ||
| 2017-03-14 | WITTE OWEN N. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,130 17,130 owned after | $83.89 exercise price | 2017-03-16 | |
| 2017-03-09 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −21,118 155,394 owned after | $1.35 exercise price | 2017-03-10 | |
| 2017-03-01 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −18,000 68,000 owned after | $6.89 exercise price | 2017-03-02 | |
| 2017-03-01 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option(Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −60,000 163,000 owned after | $6.89 exercise price | 2017-03-02 | |
| 2017-03-01 | DOUMANI ROY Director | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −50,000 75,065 owned after | $1.35 exercise price | 2017-03-02 | |
| 2017-03-01 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,400 161,301 owned after | $53.90 exercise price | 2017-03-02 | |
| 2017-03-01 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −28,882 176,512 owned after | $1.35 exercise price | 2017-03-01 | |
| 2017-02-28 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −31,601 52,499 owned after | $51.43 exercise price | 2017-03-02 | |
| 2017-02-28 | Kim Helen Susan Officer (EVP, Business Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,299 163,701 owned after | $53.90 exercise price | 2017-03-02 | |
| 2017-02-27 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 205,394 owned after | $1.35 exercise price | 2017-03-01 | |
| 2017-02-01 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 86,000 owned after | $6.89 exercise price | 2017-02-06 | |
| 2017-01-31 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 215,394 owned after | $1.35 exercise price | 2017-02-01 | |
| 2017-01-06 | Wiezorek Jeffrey Officer (SVP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,500 87,500 owned after | $6.89 exercise price | 2017-01-10 | |
| 2017-01-06 | BUTITTA CYNTHIA M Officer (Chief Operating Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 225,394 owned after | $1.35 exercise price | 2017-01-10 | |
| 2017-01-03 | CLARK IAN T Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,130 17,130 owned after | $45.95 exercise price | 2017-01-05 |